SOHO 2023 | Updates on the use of CAR-T therapy in MCL
Tycel Phillips, MD, City of Hope, Duarte, CA, shares some insights into the use of CAR-T therapy in mantle cell lymphoma (MCL), highlighting the use of brexucabtagene autoleucel (brexu-cel) as a mainstay treatment in recent years. Dr Phillips comments on the rates of immune effector cell-associated neurotoxicity syndrome (ICANS) observed with the use of this agent, as well as relapse rates. Dr Phillips also talks on lisocabtagene maraleucel (liso-cel), which has not yet been investigated in patients with MCL, but has demonstrated a similar efficacy to brexu-cel with a significantly reduced incidence of ICANS. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
